MOLECULAR BIOLOGIST

About Integra Integra Therapeutics is a biotechnology company that is creating next-generation gene writing tools to make advanced therapies safer more effective.
The technology is based on the CRISPR systems, which has been merged with transposase and integrase proteins that have a great capacity for gene transfer.
Thus, the system does not depend on viral vectors for transportating the gene-editing components into cell both ex vivo and in-vivo.
The company was founded in as a spin-off of Pompeu Fabra University (UPF) by Dr Marc Güell and Dr Avencia Sánchez-Mejías and is based in Barcelona.
It is supported by international investors (AdBio Partners, Columbus Venture Partners, Invivo Capital and Takeda Ventures) and organizations in the healthcare and biomedicine sector.
More information.
www.
ntegra-tx.
om.
Job description We are seeking a motivated Scientist to contribute to the molecular characterization of editing and insertional events of novel tools for gene therapeutic solutions.
The candidate will participate in a highly translational project with interactions with academic institutions, industry and clinicians.
Expected starting date.
December .
Requirements PhD in biology, biotechnology, genetics, experimental or health sciences.
Relevant laboratory experience in molecular biology, genome engineering, nucleic acid analysis and/or gene editing.
Extensive experience in custom library-prep for NGS, qPCR and ddPCR.
Curiosity and motivation in applied genetic engineering and synthetic biology and its translational intro clinic.
Prevoius experience in excellent execution and project management of highly competitive research projects.
Good time management and communication skills.
Excellent team player who enjoys working in a fast-evolving research environment.
Benefits of the opening The candidate will receive a full-time contract, and a competitive annual fixed salary according to the merits and experience of the candidate.
She/he will be able to receive adquate training and career growth plan.